Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)

NCT06181994 · View on ClinicalTrials.gov ↗

Study Summary

This multi-center retrospective cohort study aims to investigate the real-world outcomes of chronic subdural hematoma treated with MMAE, including clinical effectiveness, recurrence rates, and safety profile.

Conditions Studied

Study Locations (19)

Florida

  • Baptist Health South Florida, Inc. — Coral Gables
  • Mayo Clinic Florida — Jacksonville
  • Orlando Regional Medical Center — Orlando

Massachusetts

  • Massachusetts General Hospital — Boston
  • Beth Israel Deaconess Medical Center (BIDMC)/Harvard Medical School — Boston
  • Lahey Hospital and Medical Center — Burlington

Ontario

  • Unity Health Toronto — Toronto
  • University of Toronto — Toronto
  • Toronto Western Hospital — Toronto

Illinois

  • University of Illinois Chicago — Chicago
  • University of Chicago Medicine — Chicago

Pennsylvania

  • Geisinger Health — Danville
  • Thomas Jefferson University — Philadelphia

Texas

  • UTHealth Houston — Houston
  • HCA Houston Healthcare Kingwood — Kingwood

Iowa

  • The University of Iowa — Iowa City

Minnesota

  • Mayo Clinic — Rochester

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2023-12-05
Est. Completion 2026-08

Sponsor

Montefiore Medical Center

280 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06181994

The ClinicalTrials.gov registry entry for NCT06181994 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 280 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Chronic Subdural Hematoma appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06181994 reports 19 study locations spanning 10 distinct geographic areas — top geographies include Florida, Massachusetts, Ontario. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06181994 about?

NCT06181994 is a clinical study titled "Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)". This multi-center retrospective cohort study aims to investigate the real-world outcomes of chronic subdural hematoma treated with MMAE, including clinical effectiveness, recurrence rates, and safety profile.

What is the current status of trial NCT06181994?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2023-12-05. Estimated completion is 2026-08.

What conditions does trial NCT06181994 study?

This clinical trial studies the following conditions: Chronic Subdural Hematoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT06181994?

This trial is sponsored by Montefiore Medical Center, which has 280 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06181994 being conducted?

This trial has 19 study locations across Florida, Illinois, Iowa, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial